JP2020533004A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020533004A5 JP2020533004A5 JP2020514709A JP2020514709A JP2020533004A5 JP 2020533004 A5 JP2020533004 A5 JP 2020533004A5 JP 2020514709 A JP2020514709 A JP 2020514709A JP 2020514709 A JP2020514709 A JP 2020514709A JP 2020533004 A5 JP2020533004 A5 JP 2020533004A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nos
- antibody
- axl
- cdr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 claims 16
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 13
- 239000003814 drug Substances 0.000 claims 10
- 239000012634 fragment Substances 0.000 claims 9
- 229940079593 drug Drugs 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 7
- 239000000611 antibody drug conjugate Substances 0.000 claims 5
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 5
- 238000000034 method Methods 0.000 claims 4
- 239000002539 nanocarrier Substances 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000013603 viral vector Substances 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 101150022345 GAS6 gene Proteins 0.000 claims 2
- 108010023337 axl receptor tyrosine kinase Proteins 0.000 claims 2
- 125000000837 carbohydrate group Chemical group 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000003102 growth factor Substances 0.000 claims 2
- 239000002502 liposome Substances 0.000 claims 2
- 239000002105 nanoparticle Substances 0.000 claims 2
- 239000002071 nanotube Substances 0.000 claims 2
- 239000002070 nanowire Substances 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 239000002096 quantum dot Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 102100031487 Growth arrest-specific protein 6 Human genes 0.000 claims 1
- 101000923005 Homo sapiens Growth arrest-specific protein 6 Proteins 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 241000713666 Lentivirus Species 0.000 claims 1
- 108700011259 MicroRNAs Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 238000012230 antisense oligonucleotides Methods 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000003040 circulating cell Anatomy 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 238000002059 diagnostic imaging Methods 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 238000003364 immunohistochemistry Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 238000012634 optical imaging Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762557870P | 2017-09-13 | 2017-09-13 | |
| US62/557,870 | 2017-09-13 | ||
| PCT/CA2018/051108 WO2019051586A1 (en) | 2017-09-13 | 2018-09-10 | AXL SPECIFIC ANTIBODIES AND USES THEREOF |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020533004A JP2020533004A (ja) | 2020-11-19 |
| JP2020533004A5 true JP2020533004A5 (OSRAM) | 2021-10-21 |
| JP7366886B2 JP7366886B2 (ja) | 2023-10-23 |
Family
ID=65722200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020514709A Active JP7366886B2 (ja) | 2017-09-13 | 2018-09-10 | Ａｘｌ特異的抗体及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11739154B2 (OSRAM) |
| EP (1) | EP3681912A4 (OSRAM) |
| JP (1) | JP7366886B2 (OSRAM) |
| KR (1) | KR20200067145A (OSRAM) |
| CN (1) | CN111263770A (OSRAM) |
| AU (1) | AU2018333290A1 (OSRAM) |
| BR (1) | BR112020005011A2 (OSRAM) |
| CA (1) | CA3075531A1 (OSRAM) |
| IL (1) | IL273157A (OSRAM) |
| RU (1) | RU2020113027A (OSRAM) |
| SG (1) | SG11202002331QA (OSRAM) |
| WO (1) | WO2019051586A1 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017375631B2 (en) * | 2016-12-12 | 2023-06-15 | xCella Biosciences, Inc. | Methods and systems for screening using microcapillary arrays |
| WO2018125832A1 (en) | 2016-12-30 | 2018-07-05 | xCella Biosciences, Inc. | Multi-stage sample recovery system |
| DK3890876T3 (da) | 2018-12-06 | 2024-07-22 | Xcella Biosciences Inc | Lateral påfyldning af mikrokapillære arrays |
| CN113045664B (zh) * | 2019-11-28 | 2023-05-12 | 尚健单抗（北京）生物技术有限公司 | 一种分离的结合抗原axl的蛋白及其用途 |
| WO2021154156A1 (en) * | 2020-01-31 | 2021-08-05 | Agency For Science, Technology And Research | Anti-axl antibody and uses thereof |
| EP4092051A4 (en) * | 2020-06-18 | 2023-09-06 | Shenzhen Mindray Bio-Medical Electronics Co., Ltd | SOLUBLE ANTI-SUBTYPE CD14 ANTIBODY, KIT AND CORRESPONDING USE |
| CN115125272B (zh) * | 2021-03-29 | 2024-04-19 | 复旦大学 | 一种car-t治疗载体及其构建方法和应用 |
| AU2021451307A1 (en) * | 2021-06-16 | 2024-02-01 | Shanghai Sinobay Biotechnology Co., Ltd. | Antibody targeting axl protein and antigen binding fragment thereof, preparation method therefor and use thereof |
| WO2024253562A1 (en) * | 2023-06-06 | 2024-12-12 | Joint Stock Company "Biocad" | Monoclonal antibody or antigen-binding fragment thereof that specifically binds to axl, and use thereof |
| WO2025042968A1 (en) * | 2023-08-22 | 2025-02-27 | Integral Molecular, Inc. | Compositions and methods related to chicken recombinant heavy-chain only antibodies |
| PL446349A1 (pl) * | 2023-10-11 | 2025-04-14 | Celon Pharma Spółka Akcyjna | Przeciwciała bispecyficzne anty-AXL i anty-PD-L1 oraz ich zastosowanie w terapii, zwłaszcza w leczeniu nowotworu |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103747803B (zh) | 2011-06-22 | 2016-10-12 | 国家医疗保健研究所 | 抗axl抗体及其用途 |
| AU2012273954A1 (en) * | 2011-06-22 | 2014-01-09 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Anti-Axl antibodies and uses thereof |
| AU2015286569B2 (en) * | 2014-07-11 | 2021-04-15 | Genmab A/S | Antibodies binding AXL |
| WO2016187354A1 (en) | 2015-05-18 | 2016-11-24 | Agensys, Inc. | Antibodies that bind to axl proteins |
| CA2991805A1 (en) | 2015-07-10 | 2017-01-19 | Genmab A/S | Axl-specific antibody-drug conjugates for cancer treatment |
-
2018
- 2018-09-10 RU RU2020113027A patent/RU2020113027A/ru unknown
- 2018-09-10 CA CA3075531A patent/CA3075531A1/en active Pending
- 2018-09-10 JP JP2020514709A patent/JP7366886B2/ja active Active
- 2018-09-10 CN CN201880068759.XA patent/CN111263770A/zh active Pending
- 2018-09-10 AU AU2018333290A patent/AU2018333290A1/en not_active Abandoned
- 2018-09-10 BR BR112020005011-3A patent/BR112020005011A2/pt not_active IP Right Cessation
- 2018-09-10 US US16/646,823 patent/US11739154B2/en active Active
- 2018-09-10 SG SG11202002331QA patent/SG11202002331QA/en unknown
- 2018-09-10 EP EP18855793.8A patent/EP3681912A4/en active Pending
- 2018-09-10 WO PCT/CA2018/051108 patent/WO2019051586A1/en not_active Ceased
- 2018-09-10 KR KR1020207010151A patent/KR20200067145A/ko not_active Ceased
-
2020
- 2020-03-09 IL IL273157A patent/IL273157A/en unknown
-
2023
- 2023-06-27 US US18/342,287 patent/US20240076389A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020533004A5 (OSRAM) | ||
| JP7335290B2 (ja) | 二重特異性四価抗体並びにその製作及び使用方法 | |
| Carter et al. | Next generation antibody drugs: pursuit of the'high-hanging fruit' | |
| RU2020113027A (ru) | Axl-специфичные антитела и их применения | |
| CN110799539B (zh) | 抗4-1bb抗体及其制备和使用方法 | |
| KR101971770B1 (ko) | 이중특이성 항체 및 이의 용도 | |
| RS65480B1 (sr) | Bispecifična antitela protiv ceacam5 i cd3 | |
| CA3196809A1 (en) | Combination treatment | |
| JP7099709B2 (ja) | ヒト化抗ベイシジン抗体およびその使用 | |
| Ho et al. | Strategies for non-covalent attachment of antibodies to PEGylated nanoparticles for targeted drug delivery | |
| CN114641504A (zh) | 抗b7h4抗体及其双抗和应用 | |
| JP2024001073A5 (OSRAM) | ||
| JP7592712B2 (ja) | ガイダンス及びナビゲーションコントロールタンパク質、その製造方法及び使用方法 | |
| AU2020363041A1 (en) | Antibodies against the poliovirus receptor (PVR) and uses thereof | |
| US12415862B2 (en) | Methods and compositions | |
| WO2023022729A1 (en) | Antibodies and antigen binding fragments against cd155 methods of use thereof | |
| TW202448962A (zh) | 抗體、抗原結合片段和使用方法 | |
| US20230287143A1 (en) | Binding protein in fab-hcab structure | |
| CN109414492A (zh) | 针对cd81的人源化和嵌合单克隆抗体 | |
| EP4574844A1 (en) | Multispecific antibodies having specificity for cd47 and pdl1 | |
| CN119855617A (zh) | 人源化抗pvr抗体的药物偶联物 | |
| CN117836325A (zh) | 一种抗tnfr2抗体及其制备方法和应用 | |
| HK40082471A (en) | Binding protein having h2l2 and hcab structures | |
| HK40070445A (en) | Anti-b7h4 antibody, and bispecific antibody and use thereof | |
| JPWO2023015225A5 (OSRAM) |